JP2018509479A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509479A5
JP2018509479A5 JP2018502052A JP2018502052A JP2018509479A5 JP 2018509479 A5 JP2018509479 A5 JP 2018509479A5 JP 2018502052 A JP2018502052 A JP 2018502052A JP 2018502052 A JP2018502052 A JP 2018502052A JP 2018509479 A5 JP2018509479 A5 JP 2018509479A5
Authority
JP
Japan
Prior art keywords
composition
potato polysaccharide
potato
polysaccharide preparation
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018502052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509479A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024295 external-priority patent/WO2016160594A1/en
Publication of JP2018509479A publication Critical patent/JP2018509479A/ja
Publication of JP2018509479A5 publication Critical patent/JP2018509479A5/ja
Pending legal-status Critical Current

Links

JP2018502052A 2015-03-27 2016-03-25 哺乳動物内のアミロイドβレベルを減少させるための方法および物質 Pending JP2018509479A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139178P 2015-03-27 2015-03-27
US62/139,178 2015-03-27
PCT/US2016/024295 WO2016160594A1 (en) 2015-03-27 2016-03-25 Methods and materials for reducing amyloid beta levels within a mammal

Publications (2)

Publication Number Publication Date
JP2018509479A JP2018509479A (ja) 2018-04-05
JP2018509479A5 true JP2018509479A5 (OSRAM) 2019-05-09

Family

ID=57006339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018502052A Pending JP2018509479A (ja) 2015-03-27 2016-03-25 哺乳動物内のアミロイドβレベルを減少させるための方法および物質

Country Status (6)

Country Link
US (2) US10639322B2 (OSRAM)
EP (1) EP3273972A4 (OSRAM)
JP (1) JP2018509479A (OSRAM)
AU (1) AU2016243516A1 (OSRAM)
CA (1) CA2981138A1 (OSRAM)
WO (1) WO2016160594A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3046566B1 (en) 2013-09-19 2020-12-02 The Research Foundation for The State University of New York Methods and materials for treating liver steatosis
CA2981138A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2134714A (en) 1936-11-25 1938-11-01 Jacob A Glassman Saccharine-aspirin tablet
US3622677A (en) 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
WO1998033937A2 (de) 1997-02-03 1998-08-06 Max-Delbrück-Centrum für Molekulare Medizin GENOMISCHE SEQUENZ DES HUMANEN ν-OPIOID-REZEPTOR GENES SOWIE SEINER VARIANTEN, POLYMORPHISMEN UND MUTATIONEN
CA2280093A1 (en) 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US20050085498A1 (en) 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6376549B1 (en) 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US20030159178A1 (en) 2000-02-10 2003-08-21 Peter Ulvskov Method for remodelling cell wall polysaccharide structures in plants
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
DE10045059A1 (de) 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
AU2001295979A1 (en) 2000-10-20 2002-04-29 Ajinomoto Co., Inc. Medicinal compositions, dose and method for treating malaria
DE60224189T2 (de) 2001-06-20 2008-12-11 Merck & Co., Inc. Dipeptidylpeptidase-hemmer zur behandlung von diabetes
GB0117767D0 (en) 2001-07-20 2001-09-12 Unilever Plc Polymers and their synthesis
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
US20050214413A1 (en) 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
JP3998695B2 (ja) 2005-04-22 2007-10-31 株式会社シクロケム αリポ酸水溶液及びその製造方法
WO2006114019A1 (en) 2005-04-26 2006-11-02 Versitech Limited Polysaccharide extract from lycium barbarum as neuroprotective agent against beta-amyloid peptide neurotoxicity
US7560536B2 (en) * 2005-05-18 2009-07-14 Virginia Tech Intellectual Properties, Inc. Morning glory-derived anticancer agents, and novel ipomoeassin compounds
JP4863204B2 (ja) 2005-06-15 2012-01-25 独立行政法人産業技術総合研究所 腎症関連疾患の診断方法及び診断キット
JP5247012B2 (ja) 2006-07-25 2013-07-24 雪印メグミルク株式会社 脂肪肝抑制剤
EP2106449B1 (en) 2007-01-18 2012-09-19 Novozymes A/S Method for producing potato products
JP2009007309A (ja) 2007-06-29 2009-01-15 Riken Vitamin Co Ltd α−リポ酸含有多芯型マイクロカプセル
KR101121543B1 (ko) * 2007-07-04 2012-03-06 학교법인 선목학원 벼과식물로부터 수득되는 전분 또는 식이섬유를 포함하는허혈성 질환 및 퇴행성 뇌질환의 예방 및 치료를 위한조성물
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
JP2013506427A (ja) 2009-10-02 2013-02-28 ユニバーシティ オブ アイダホ 強化した難消化性デンプン含有量および抑制された血糖上昇応答を有するジャガイモ製品ならびにその方法
KR101093413B1 (ko) * 2009-10-05 2011-12-14 고려대학교 산학협력단 뇌 신경 세포 보호 활성을 갖는 고구마 추출물 및 그의 용도
WO2011069781A1 (en) 2009-12-11 2011-06-16 Unilever Nv Polysaccharide suitable to modulate immune response
WO2012016050A2 (en) 2010-07-28 2012-02-02 The General Hospital Corporation Chemoradiotherapy for kras-mutant colorectal cancer
JP2012149004A (ja) 2011-01-18 2012-08-09 Theravalues Corp 核内受容体の賦活剤
US8658787B2 (en) 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
HK1207082A1 (en) 2012-03-28 2016-01-22 The Research Foundation For The State University Of New York Methods and materials related to nutritional supplement compositions containing a potato polysaccharide preparation
US9814255B2 (en) * 2012-05-20 2017-11-14 Darco Natural Products Inc. Method for producing purple sweet potato juice and dried powder
US9180212B2 (en) * 2012-05-22 2015-11-10 The Regents Of The University Of California β-amyloid plaque imaging agents
JP6242336B2 (ja) 2012-09-28 2017-12-06 株式会社Bna Bnaクランプ法
GB201223365D0 (en) 2012-12-24 2013-02-06 Provexis Natural Products Ltd Compositions
CN103110657A (zh) * 2013-01-31 2013-05-22 黄仁彬 玉郎伞多糖在制备药物中的应用
CN114533753A (zh) 2013-03-15 2022-05-27 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
EP3008212A4 (en) 2013-06-10 2017-05-24 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
EP3046566B1 (en) 2013-09-19 2020-12-02 The Research Foundation for The State University of New York Methods and materials for treating liver steatosis
AU2014386236B2 (en) 2014-03-14 2019-07-11 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
CA2981138A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US20180078599A1 (en) 2015-03-27 2018-03-22 The Research Foundation For The State University Of New York Methods and materials for treating cancer
EP3429373A4 (en) * 2016-03-14 2019-07-17 Mitogenetics, LLC MATERIALS AND METHOD FOR TREATING HYPOXIC CONDITIONS

Similar Documents

Publication Publication Date Title
JP2012021005A5 (OSRAM)
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
JP2013542195A5 (OSRAM)
BR112015010203A8 (pt) composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina
BR112013025517A2 (pt) uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas
JP2018527305A5 (OSRAM)
JP2017522288A5 (OSRAM)
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
JP2018509479A5 (OSRAM)
JP2014513121A5 (OSRAM)
JP2016535762A5 (OSRAM)
US20200138776A1 (en) Composition for use in the treatment of endometriosis and symptoms associated with endometriosis
HK1209041A1 (en) A method of weight reduction
Álvarez et al. Ziprasidone versus Olanzapine in the weight gain associated with the treatment of schizophrenia: A six-month double-blind randomized parallel group study
CN106619618B (zh) 一种缬沙坦药物组合物及其制备方法
Wang et al. Glucan phosphate inhibits HMGB-1 release from rat myocardial H9C2 cells in sepsis via TLR4/NF-кB signal pathway
JP2011032256A (ja) 薬用ニンジンを始めとしたサポニン含有生薬服用時に生じるメンゲン反応の防止及び生薬の吸収性を増大させる製法(生薬の有効成分を鶏卵タンパクに吸収させる方法)による医薬組成物及び健康食品
JP2016188260A5 (OSRAM)
Lee et al. Effects of Gami-Handayeolso-Tang on Body Fat Reduction in High Fat Diet-Fed Obese Mice
Cisneros Serrano Omalizumab/prednisone
Lowry Bleeding complications in paediatric patients: 3 case reports
KR101870012B1 (ko) Tis21의 발현조절제를 유효성분으로 포함하는 비알콜성 지방간 예방 또는 치료용 조성물
Koike Interstitial pneumonia: 8 case reports
TWI507196B (zh) 赤靈酸s用於製造癌症治療藥物的新穎用途
Cucchiaro et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled pearl 2 trial